Evofem's Phexxi birth control method prevented 99% of pregnancies, post analysis shows

Jun. 16, 2022 9:53 AM ETEvofem Biosciences, Inc. (EVFM)By: Anuron Mitra, SA News Editor2 Comments

Sexual Health sign

tolgart/iStock via Getty Images

  • Evofem Biosciences (NASDAQ:EVFM) on Thursday said a post analysis of its phase 3 trial evaluating Phexxi showed that the birth control method prevented 99% of pregnancies.
  • The analysis was based on 101 pregnancies in about 1.2K women who used Phexxi over 24.2K acts of intercourse.
  • Phexxi was approved by the U.S. FDA in May 2020 based on the results of the late-stage trial, called AMPOWER, which enrolled about 1.3K women in the U.S., as well as combined safety data from AMPOWER and a previous late-stage trial called AMP-001.
  • EVFM's Phexxi works by modulating vaginal pH levels which in turn immobilizes the sperm. Phexxi is not effective when used after intercourse.
  • EVFM stock -3.1% to $0.29 in morning trading.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.